Led · Debt Financing · Sep 2022

Gogoro develops and sells Internet-connected electric scooters and runs a proprietary battery-swapping infrastructure that allows riders to exchange depleted batteries in seconds. The company commands its home market, recording more than 63,000 e-scooter registrations in Taiwan during the first 11 months of 2021—far ahead of any competitor—and has more than 450,000 battery-swapping subscribers. To accelerate international expansion, Gogoro has struck partnerships with major two-wheeler manufacturers such as Hero MotoCorp in India and Yadea in China, enabling those OEMs to build vehicles around Gogoro’s swap technology while co-building local swap networks. Over the past five years the company has generated more than $1 billion in cumulative revenue, yet it remains unprofitable as it invests heavily in scale. Management believes fresh capital will fund new market launches and help the business reach break-even. The company is preparing to merge with Poema Global, a SPAC, which will further bolster its capital base.

Participated · Series A · Aug 2021

安立玺荣 is an innovative immunotherapy new‑drug developer committed to R&D for cancer, immune and neurological disease treatments. The company provides products including Alzheimer’s drugs and antibody biologics. It recently announced completion of a financing round totaling nearly RMB 100 million equivalent in USD‑denominated funds. The financing was supported by three dollar funds. The company said the round reflects international and domestic investors' recognition of its scientific innovation and execution capabilities. The report was published by DoNews citing IT桔子. Elixiron is developing therapeutics across cancer, neurological diseases and inflammatory disorders with a focus on reverse-translational immunotherapy approaches. The company operates in San Francisco, Taipei and Shanghai and was founded in 2017 under CEO and Chairman Hung-Kai Chen. It intends to use the Series A-1 funds to advance phase 1 trials of two pipeline candidates and to take three immuno-oncology assets toward IND applications. Pipeline highlights include EI-1071, an orally available, potent CSF1R inhibitor currently in a phase 1 trial and supported by an Alzheimer’s Association Part the Cloud‑Gates Partnership Grant, and EI-001, a fully human antibody targeting immuno-modulatory pathways in vitiligo and chronic hepatitis B. The executive team includes Pandelakis Koni (Executive VP of R&D) and Carrie Duan (Executive VP of Clinical Development).